Marathon Capital Management Reduces Stake in Pfizer Inc. $PFE

Marathon Capital Management lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 82.9% during the 3rd quarter, Holdings Channel.com reports. The fund owned 17,035 shares of the biopharmaceutical company’s stock after selling 82,475 shares during the period. Marathon Capital Management’s holdings in Pfizer were worth $434,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer in the third quarter valued at approximately $29,000. Howard Hughes Medical Institute purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $30,000. True Wealth Design LLC lifted its position in shares of Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at $32,000. Finally, Evelyn Partners Asset Management Ltd purchased a new position in shares of Pfizer in the 2nd quarter valued at $33,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. HSBC reiterated a “buy” rating and set a $29.00 price target on shares of Pfizer in a research note on Wednesday, December 10th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Monday, March 2nd. Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.05.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Pfizer Stock Performance

Shares of PFE opened at $26.60 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The company has a 50-day simple moving average of $26.50 and a 200-day simple moving average of $25.52. The company has a market capitalization of $151.23 billion, a PE ratio of 19.56 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The firm’s revenue was down 1.2% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.